newsfilter
← Earnings
Earnings Releases·

Shattuck Labs — Third Quarter 2026 Earnings Summary

Shattuck Labs initiated the RECEPTIVE-CD1 Phase 2b clinical trial for its lead candidate SL-325 in Crohn's disease, with 12-week induction data expected in the first half of 2028. The company also announced plans to begin the RECEPTIVE-HS1 Phase 2 trial for SL-325 in hidradenitis suppurativa during the fourth quarter of 2026. For its bispecific candidate SL-846, Shattuck presented preclinical data demonstrating durable blockade of TL1A and IL-23 signaling in non-human primates, with a Phase 1 trial anticipated to start in 2027. Financially, the company reported a net loss of $25.2 million for the third quarter of 2026 and holds $196.3 million in cash and investments, which is projected to fund operations through 2029.

Company
SHATTUCK LABS INC
Sector
Healthcare
Industry
Biotechnology